News & Investors

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Cara Therapeutics Announces Summary Data From Phase 1 Trial of Oral CR845 in Hemodialysis Patients with Chronic Kidney Disease
Tablet strengths exhibiting appropriate plasma levels identified for potential use in general CKD-associated pruritus patients
View HTML
Toggle Summary Cara Therapeutics Announces Top-line Results From Phase 2b Trial of Oral CR845 in Chronic Pain Patients With Osteoarthritis of the Hip or Knee
- Statistically significant 39 percent reduction in mean joint pain score in hip patients at eight weeks with 5.0 mg dose - - 35 percent reduction in mean joint pain score for all patients at eight weeks with 5.0 mg dose - - All tablet strengths well tolerated over eight-week treatment period - -
View HTML
Toggle Summary Cara Receives Breakthrough Therapy Designation from FDA for I.V. CR845 for the Treatment of Chronic Kidney Disease-Associated Pruritus in Hemodialysis Patients
Phase 3 safety extension trial underway
View HTML
Toggle Summary Cara Therapeutics Reports Continuation of Phase 3 Trial of I.V. CR845 in Postoperative Pain Following Interim Assessment
- Trial will continue to test two doses of CR845 and aims to enroll up to 450 patients - - Both doses of CR845 well tolerated - - Trial completion expected in the fourth quarter of 2017 - STAMFORD, Conn. , June 21, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc.
View HTML
Toggle Summary Cara Therapeutics to Present at the 17th Annual Conference on Pain Therapeutics
Dr. Joseph Stauffer to deliver opening remarks and discuss kappa opioid receptor agonists as a novel approach to acute and chronic pain management Dr. Stauffer serves as co-chair and on the event's Scientific Advisory Board STAMFORD, Conn. , May 17, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc.
View HTML
Toggle Summary Cara Therapeutics to Host KOL Meeting on Chronic Kidney Disease-Associated Pruritus on May 16, 2017
STAMFORD, Conn. , May 12, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that
View HTML
Toggle Summary Cara Therapeutics Reports First Quarter 2017 Financial Results
- Reported statistically significant positive top-line results from Part A of Phase 2/3 trial for I.V. CR845 in chronic kidney disease (CKD)-associated pruritus -  - Completed public offering of common stock, raising net proceeds of $86.5 million -  - Conference call today at 4:30 p.m.
View HTML
Toggle Summary Cara Therapeutics to Announce First Quarter 2017 Financial Results on May 4, 2017
STAMFORD, Conn. , April 27, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced
View HTML
Toggle Summary Cara Therapeutics Announces Positive Data From Quantitative Phase 1 Trial Measuring Respiratory Safety of I.V. CR845
- I.V. CR845 statistically equivalent to placebo across all measures of respiratory safety -
View HTML
Toggle Summary Cara Therapeutics Announces Closing of Its Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
STAMFORD, Conn. , April 05, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics , Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced
View HTML